Коррекция липидных нарушений у больных сахарным диабетом типа 2 в соответствии с современными международными стандартами и рекомендациями
- Авторы: Сусеков А.1
-
Учреждения:
- РКНПК Минздравсоцразвития РФ
- Выпуск: Том 23, № 4 (2012)
- Страницы: 19-22
- Раздел: Статьи
- URL: https://journals.eco-vector.com/0236-3054/article/view/115418
- ID: 115418
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
В статье обсуждаются основные принципы медикаментозной коррекции липидных нарушений у больных сахарным диабетом типа 2 в соответствии с современными американскими и европейскими научными рекомендациями.
Ключевые слова
Полный текст
Об авторах
А. Сусеков
РКНПК Минздравсоцразвития РФ
Email: asus99@mail.ru
доктор медицинских наук Москва
Список литературы
- Catapano A., Backer G., Graham I. et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)//Atherosclerosis. - 2011; 217: 3-46.
- Executive Summary: Standards of Medical Care in Diabetes//Diabetes Care 35. -2012; 1: 4-10.
- The ACCORD Study Group. Effects of combination lipid-lowering therapy in type Diabetes Mellitus. New Engl. J. Med. 2010. Epub ahead a print. NEJM//Org. N. Engl. J. Med. - 2010; 362 (17): 1563-1574.
- Robinson J., Stone N. et al. Identifying patients for aggressive cholesterol lowering: the risk curve concept//Am. J. Cardiology. - 2006; 98: 1405-1408.
- Haffer S., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects with and without myocardial inf arction//N. Engl. J. Med. - 1998; 339: 229-234.
- Stamler J., Vaccano O., Neaton J. et al. Diabetes, other risk-factors, and 12-year mortality for men, screened in the Multiply Risk Factor Intervention//Trial. Diabetes. Care. - 1993; 16: 434-444.
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)//Lancet. - 1994; 344: 1383-1389.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial//Lancet. - 2002; 360: 7-22.
- Colhoun H., Betteridge D., Durrington P. et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS)//Diabetologia. - 2005; 48 (12): 2482-2485.
- Shepherd J., Barter P., Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to New Targets (TNT) Study//Diabetes. Care.- 2006; 29: 1220-1226.
- Steiner G., Stewart D., Hosking J. Baselinecharacteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes//Am. J. Cardiol. - 1999; 84 (9): 1004-1010.
- Rubins H., Robins S., Collins D. et al. Diabets, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veteran Affaires high-density lipoprotein intervention trial (VA-HIT)//Arch. Intern. Med. - 2002; 162 (22): 2597-2604.
- Frick M., Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment; changes in risk factors, and incidence of coronary heart disease//N. Engl.J. Med. - 1987; 317: 1237-1245.
- Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study//Circulation. - 2000; 102: 21-27.
- Keech A., Simes R., Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial//Lancet. - 2005; 366 (9500): 1849-1861.
- Grundy S., Vega G., Tomassini J. et al. Correlation of non-high density lipoprotein cholesterol and low-density lipoprotein cholesterol with apoplipoprotein B during simvsatatin+fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)//Am. J. Cardiol. - 2009; 104 (4): 548-553.
- Jun M., Foote C., Lv J. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis//Lancet. - 2010; 375: 1875-1884.
Дополнительные файлы
